🚨 Top 5 Takeaways from our 2024 Biopharma Wrap-Up 🚨
Every 6 months, my team and I review biopharma R&D and investment decisions. Our latest report examines 2024. Much of the last year was shaped by the ongoing race to fill impending revenue gaps as older drugs face LOE. More below 👇
about 1 year ago